Ghassan Abou-Alfa, MD of Memorial Sloan-Kettering discusses the impact of regorafenib for hepatocellular carcinoma (HCC) treatment. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Advertisement